clinical trials
7 articles tagged with ‘clinical trials’
What the Human Evidence Actually Shows: A Peptide Evidence Map
Thymosin beta-4 has been through a Phase 3 trial. It was an eye drop, in a corneal disease, and it missed. A five-tier map of where each peptide's evidence actually sits, and why a registered trial that never published is weaker than no trial at all.
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
Retatrutide in Canada: Access, Trials, and Approval Timing
Retatrutide is not yet approved in Canada; access is limited to clinical trials. This article outlines the current status, evidence, and realistic timelines for availability.
Semaglutide vs Tirzepatide vs Retatrutide: A Research Comparison of GLP-1 Receptor Agonist Peptides
An evidence-based comparison of three incretin-based research peptides — semaglutide (GLP-1), tirzepatide (GIP/GLP-1), and retatrutide (GIP/GLP-1/glucagon) — covering receptor pharmacology, clinical trial data from the STEP, SURMOUNT, and Phase 2 retatrutide programs, stability considerations, and analytical quality benchmarks.
Novo Nordisk Presents Oral Semaglutide Phase 3a Trial Data at ADA
Novo Nordisk shared recent findings from two phase 3a trials of oral Semaglutide at the American Diabetes Association annual meeting. The drug reduced A1C levels and supported weight loss in type 2 diabetes patients compared to controls. Results from PIONEER 2 and PIONEER 4 trials showed significant improvements in blood sugar control and body weight.
Atosiban Serves as Maintenance Therapy for Preterm Labor
Atosiban, an oxytocin-receptor antagonist marketed in China in 2006, offers maintenance treatment to manage preterm labor risks after initial tocolysis. Clinical trials show it delays delivery better than placebo in some cases and has fewer side effects than beta-2 agonists. Studies highlight its safety and role in reducing recurrent preterm labor episodes.
.jpg)
Abaloparatide Reduces Osteoporotic Spine Fractures by 84%
Abaloparatide, an analog of human PTHrP (1-34), shows strong potential in treating osteoporosis by boosting bone formation while limiting resorption. Animal studies confirm its ability to reverse bone loss in ovariectomy models, and a phase 3 trial revealed an 84% lower risk of new spine fractures at 43 months compared to placebo. This peptide offers advantages over traditional antiresorptives by improving bone strength and density.